Literature DB >> 17557771

Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.

Jean Bourbeau1, Pota Christodoulopoulos, Francois Maltais, Yasuhiro Yamauchi, Ronald Olivenstein, Qutayba Hamid.   

Abstract

BACKGROUND: Airway inflammation in chronic obstructive pulmonary disease (COPD) is characterised by infiltration of CD8+ T cells and CD68+ macrophages and an increased number of neutrophils, whereas few studies have described the presence of eosinophils. Although the anti-inflammatory effects of corticosteroids in stable COPD are unclear, recent studies suggest that combination therapy could be beneficial. A study was therefore undertaken to evaluate combined salmeterol/fluticasone propionate (SFC) and fluticasone propionate (FP) alone on inflammatory cells in the airways of patients with COPD.
METHODS: Patients were treated in a randomised, double blind, parallel group, placebo-controlled trial with either a combination of 50 microg salmeterol and 500 microg FP twice daily (SFC, n = 19, 19 men, mean age 62 years), 500 microg FP twice daily (n = 20, 15 men, mean age 64 years) or placebo (n = 21, 17 men, mean age 66 years) for 3 months. At the start and end of treatment bronchoscopy with bronchial biopsies was performed and the numbers of CD8+ T lymphocytes, CD68+ macrophages, neutrophils and eosinophils were measured.
RESULTS: CD8+ cells were significantly reduced by SFC compared with placebo (difference -98.05 cells/mm(2); 95% CI -143.14 to -52.9; p<0.001). Such a marked effect was not seen with FP alone (-44.67 cells/mm(2); 95% CI -90.92 to 1.57; p = 0.06). CD68+ macrophages were also reduced by SFC compared with placebo (difference -31.68 cells/mm(2); 95% CI -61.07 to -2.29; p = 0.03) but not by FP. SFC did not significantly change neutrophils and eosinophils compared with placebo.
CONCLUSIONS: SFC has airway anti-inflammatory effects not seen with inhaled corticosteroids alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17557771      PMCID: PMC2117108          DOI: 10.1136/thx.2006.071068

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  39 in total

Review 1.  Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

Authors:  M Johnson; S Rennard
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 2.  Neutrophils and the pathogenesis of COPD.

Authors:  Robert A Stockley
Journal:  Chest       Date:  2002-05       Impact factor: 9.410

Review 3.  Molecular interactions between glucocorticoids and long-acting beta2-agonists.

Authors:  Ian M Adcock; Kittipong Maneechotesuwan; Omar Usmani
Journal:  J Allergy Clin Immunol       Date:  2002-12       Impact factor: 10.793

4.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils.

Authors:  D Stănescu; A Sanna; C Veriter; S Kostianev; P G Calcagni; L M Fabbri; P Maestrelli
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

5.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.

Authors:  Donald A Mahler; Patrick Wire; Donald Horstman; Chai-Ni Chang; Julie Yates; Tracy Fischer; Tushar Shah
Journal:  Am J Respir Crit Care Med       Date:  2002-10-15       Impact factor: 21.405

6.  Ongoing airway inflammation in patients with COPD who do not currently smoke.

Authors:  S R Rutgers; D S Postma; N H ten Hacken; H F Kauffman; T W van Der Mark; G H Koëter; W Timens
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 7.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials.

Authors:  Abdullah Alsaeedi; Don D Sin; Finlay A McAlister
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

8.  The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.

Authors:  Keith L Hattotuwa; Mariusz J Gizycki; Tareq W Ansari; Peter K Jeffery; Neil C Barnes
Journal:  Am J Respir Crit Care Med       Date:  2002-06-15       Impact factor: 21.405

9.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study.

Authors:  P K Jeffery; P Venge; M J Gizycki; I Egerod; R Dahl; P Faurschou
Journal:  Eur Respir J       Date:  2002-12       Impact factor: 16.671

10.  Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease.

Authors:  G Pitsiou; G Kyriazis; O Hatzizisi; P Argyropoulou; E Mavrofridis; D Patakas
Journal:  Respir Med       Date:  2002-08       Impact factor: 3.415

View more
  44 in total

1.  Reducing inflammation in COPD: the evidence builds.

Authors:  Neil Barnes
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

Review 2.  A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.

Authors:  M A Giembycz; M Kaur; R Leigh; R Newton
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

Review 3.  Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches.

Authors:  John A Marwick; Ian M Adcock; Kian Fan Chung
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 4.  Resolution of cell-mediated airways diseases.

Authors:  Carl G Persson; Lena Uller
Journal:  Respir Res       Date:  2010-06-11

Review 5.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Toby J Lasserson; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 6.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 7.  Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.

Authors:  Luis Javier Nannini; Phillippa Poole; Stephen J Milan; Rebecca Holmes; Rebecca Normansell
Journal:  Cochrane Database Syst Rev       Date:  2013-11-10

Review 8.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.

Authors:  Agnes Kliber; Larry D Lynd; Don D Sin
Journal:  Respir Res       Date:  2010-05-11

Review 10.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.

Authors:  Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc
Journal:  Can Respir J       Date:  2007-09       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.